<DOC>
	<DOCNO>NCT02317393</DOCNO>
	<brief_summary>The purpose study evaluate contribution image expression intégrines αvβ3 characterization residual mass non-seminoma tumor end chemotherapy . The investigator hope result first stage clinical trial come consolidate preclinical result obtain investigator team characterize interest strong contribution use tracer rest expression αvβ3 integrine diagnosis simple necrose mass end treatment non-seminoma tumor , allow defer surgery 40 % patient .</brief_summary>
	<brief_title>Contribution Imaging Expression intégrines αvβ3 Characterization Residual Masses Non-seminoma Tumors End Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<criteria>Man woman age 18 year Patients one several ganglionic visceral residual mass ( &gt; 1 cm ) chemotherapy metastatic nonseminoma testicular tumor , surgery plan ; Affiliate social security system ; Signed write Informed consent Patient deprive liberty result justice administrative decision Any medical psychological condition could compromise capacity patient participate study ; Previous concomitant cancer 5 year except basal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Nuclear medicine</keyword>
	<keyword>Positron emission tomography</keyword>
	<keyword>avb3 integrin expression</keyword>
</DOC>